Mission Statement, Vision, & Core Values of Sensus Healthcare, Inc. (SRTS)

When you assess a medical device company like Sensus Healthcare, Inc. (SRTS), the core values aren't just wall decorations; they are the engine driving the financials, especially with nine-month 2025 revenues hitting $22.5 million against a net loss of $4.6 million. That Mission-to make Superficial Radiation Therapy (SRT) the primary, non-invasive skin cancer treatment-is what justifies the investment in R&D and the shift in reimbursement codes. Do you really know how their commitment to Honesty and Integrity translates into the business model, or are you just looking at the top-line revenue drop from last year?

For a company focused on patient-centric care and innovation, especially one that shipped 56 SRT systems in the first nine months of 2025, understanding their Vision is defintely the key to mapping near-term risks. We need to look past the current $4.6 million loss and see how their Core Values, like Quality and Patient Care, will help them capitalize on the new CMS coding validation that just hit in November 2025.

Sensus Healthcare, Inc. (SRTS) Overview

You're looking for a clear picture of Sensus Healthcare, Inc., a medical device company that's carved out a strong niche in non-invasive skin treatments. The direct takeaway is that Sensus Healthcare specializes in Superficial Radiation Therapy (SRT) systems, a non-surgical alternative for non-melanoma skin cancer and keloids, and while 2025 revenue is down year-over-year, a major regulatory win with CMS is setting the stage for a significant rebound.

Sensus Healthcare, Inc. was founded in 2010 in Boca Raton, Florida, with a focus on bringing a non-invasive, cost-effective treatment to the dermatology and oncology markets. They quickly acquired the assets for the SRT-100 system, which uses low-energy photon radiotherapy to treat skin conditions. This technology is a modern culmination of decades-old orthovoltage therapy, but with advanced precision and patient-friendly application. Honestly, they saw a gap in the market for a gentler cancer treatment, and they filled it.

Their core product line includes the SRT-100™, the SRT-100+™, and the flagship SRT-100 Vision™ system, which integrates high-frequency ultrasound for Image-Guided Superficial Radiation Therapy (IGSRT). Their mission is to be the worldwide leader for non-invasive skin cancer treatment, providing a safe and effective cure that maintains a patient's dignity and quality of life. For the nine months ended September 30, 2025, the company reported total revenue of approximately $22.5 million.

• Founded in 2010; headquartered in Boca Raton, Florida.
• Main products: SRT-100™ series for non-melanoma skin cancer and keloids.
• Nine-month 2025 revenue: $22.5 million.

2025 Financial Performance: Near-Term Headwinds and Strategic Tailwinds

To be fair, the company's 2025 financial performance has been mixed, but the underlying operational metrics point to a strong future. For the third quarter of 2025, Sensus Healthcare reported revenues of $6.9 million, which was a decrease compared to the $8.8 million reported in the same quarter of 2024. This slowdown, largely due to fewer unit sales to a major customer, resulted in a net loss of $0.9 million for Q3 2025, bringing the net loss for the first nine months of 2025 to $4.6 million.

What this estimate hides is the significant growth in their Fair Deal Agreement (FDA) program, which is a key long-term revenue driver. The treatment volume from these agreements-where practices pay per treatment rather than buying the system outright-increased by 20% sequentially in Q3 2025 over the second quarter, and by a massive 52% compared to Q1 2025. That's a defintely positive sign for future recurring revenue. Plus, they shipped 16 SRT systems in Q3 2025, including three units internationally to China, showing continued global expansion. They also exited the quarter with a strong cash position of $24.5 million and no debt, which gives them plenty of runway.

A Leader in Non-Invasive Skin Cancer Treatment

Sensus Healthcare is not just another medical device company; they are a clear leader in the specialized field of Superficial Radiation Therapy. They are focused, and that specialization gives them an edge over larger, more diversified competitors. In fact, one industry ranking places them as the 1st among 16 active competitors in their specific niche, a testament to their focused strategy.

The biggest news, and the clearest indicator of their industry standing, is the recent announcement from the Centers for Medicare & Medicaid Services (CMS). CMS established first-ever dedicated CPT® codes for SRT in late 2025. This is a monumental validation of their technology, providing compelling economics and reimbursement certainty for physician partners. This regulatory alignment is expected to significantly boost adoption by leveling the playing field between office-based and hospital outpatient rates. This is a game-changer for demand. If you want to dive deeper into who is betting on this success, you should check out Exploring Sensus Healthcare, Inc. (SRTS) Investor Profile: Who's Buying and Why?

The company's success isn't just about selling a machine; it's about establishing a new, non-surgical standard of care. They are positioned to capture a larger share of the non-melanoma skin cancer market, especially now that reimbursement is more certain. Your next step should be to map out the projected revenue growth based on the new CMS codes' impact starting in 2026. Finance: model the CPT code impact on 2026 revenue by month-end.

Sensus Healthcare, Inc. (SRTS) Mission Statement

You're looking for the bedrock of Sensus Healthcare, Inc.'s strategy, and honestly, you won't find a single, framed statement. The mission is better understood as a three-part operating mandate: to pioneer non-invasive, cost-effective skin treatments; to drive innovation in radiation oncology; and to deliver a highly effective, patient-centric platform globally. This mandate guides every capital allocation decision, like the significant jump in Research and Development (R&D) spending we saw in the first half of 2025.

The significance of this mission is clear when you look at the financials. For the first nine months of 2025, Sensus Healthcare reported total revenues of $22.5 million, a figure intrinsically tied to the adoption of their Superficial Radiation Therapy (SRT) technology. When a company's purpose is this tightly woven into its product, the mission statement isn't just marketing-it's the business model. You can dig deeper into how these numbers impact the stock in Breaking Down Sensus Healthcare, Inc. (SRTS) Financial Health: Key Insights for Investors.

Core Component 1: Pioneering Non-Invasive, Cost-Effective Treatment

The first pillar of the Sensus Healthcare mission is to provide an alternative to surgery for common skin conditions, specifically non-melanoma skin cancers and keloids. They specialize in treatments that are highly effective, non-invasive, minimally-invasive, and cost-effective. This focus on cost-effectiveness is a major driver of their recurring revenue model, known as the Fair Deal Agreement (FDA).

This model is defintely working. In the second quarter of 2025, the treatment volume from their FDA-based SRT systems increased by a remarkable 27% sequentially over the first quarter. Here's the quick math: more patients getting treated means more recurring revenue, which helps stabilize the business even when unit sales fluctuate. For the first nine months of 2025, the company shipped 56 SRT systems, a lower number than the prior year, but the growth in recurring treatment volume signals a healthy shift in their business mix.

Core Component 2: Driving Innovation in Radiation Oncology

The second critical component is a dedication to driving innovation in radiation oncology. This isn't just about selling a machine; it's about continuously improving the technology to be safer and more precise. Their product portfolio, which includes the SRT-100™, SRT-100+™, and the advanced SRT-100 Vision™ with integrated high-frequency ultrasound imaging, shows this commitment to cutting-edge technology.

The financial commitment to this pillar is substantial. Research and development (R&D) expense for the first half of 2025 jumped to $4.1 million, a significant increase from $1.8 million in the first half of 2024. This investment covers lobbying for favorable billing code reimbursement and product development, showing they are willing to spend cash now to secure future revenue streams. It's a realist's move: you have to fight for reimbursement to make your innovation viable.

• Invest in R&D: $4.1 million in H1 2025.
• Secure quality: Achieved MDSAP certification for full SRT portfolio.
• Enhance precision: SRT-100 Vision includes volumetric tumor analysis.

Core Component 3: Delivering a Highly Effective, Patient-Centric Platform

The final component centers on the patient and the healthcare provider. The mission is to provide a patient-centric treatment platform that is safe, precise, and adaptable to various clinical settings. This focus is what translates clinical efficacy into commercial success, especially in the competitive US market.

A clear action showing this commitment is the achievement of the Medical Device Single Audit Program (MDSAP) certification for their entire SRT product portfolio in 2025. This certification is not trivial; it streamlines regulatory access globally, which means more patients worldwide can benefit from the technology. What this estimate hides, of course, is the sheer cost and time required to meet these rigorous international quality standards. Still, it's a necessary step to expand their market reach beyond the US, where they generate the majority of their revenue. As of September 30, 2025, the company had a strong cash position of $24.5 million, giving them the capital to pursue this global expansion and maintain high service levels.

Sensus Healthcare, Inc. (SRTS) Vision Statement

You're looking at Sensus Healthcare, Inc. (SRTS) and trying to map their stated purpose to their financial execution, which is smart. The company's vision isn't a single, neat sentence on a plaque; it's a three-part operating philosophy: be the global pioneer in non-invasive radiotherapy, ensure patient-centric, accessible care, and drive strategic, profitable growth through innovation like the Fair Deal Agreement (FDA) program.

Honestly, the market is watching their execution on that last point right now, especially after a challenging first nine months of 2025. Their total revenue for the first nine months of 2025 was $22.5 million, down from the prior year, mostly due to lower unit sales to a large customer. But still, the long-term vision is clear: dominate the superficial radiotherapy (SRT) market and expand their technology's application.

Pioneering Non-Invasive Superficial Radiotherapy (SRT)

The core of Sensus Healthcare's vision is to be the definitive global leader in non-invasive treatments for skin cancer and keloids. They are a pioneer in superficial radiotherapy (SRT) and image-guided superficial radiotherapy (IG-SRT) technology, which offers a non-surgical alternative for patients. This isn't just marketing fluff; it's a distinct value proposition in oncology.

Their global installed base of SRT systems surpassed 900 units by the third quarter of 2025, and they are targeting the 1,000-system milestone in 2026. This expanding footprint is the most concrete measure of their pioneering success. The near-term risk, though, is that the decrease in unit sales-only 16 systems shipped in Q3 2025 compared to 27 in Q3 2024-shows a reliance on key customers that needs diversification. That's a defintely a point to watch.

Commitment to Patient-Centric and Accessible Care

The mission statement is built on providing accessible, effective, and patient-friendly treatment options that enhance quality of life. This translates directly into their business model, specifically the Fair Deal Agreement (FDA) program, which is a major catalyst for adoption. The FDA program allows clinics to lease the SRT systems and share in the revenue, which drastically lowers the upfront capital expenditure (CapEx) barrier for healthcare providers.

This model is working: the treatment volume from the FDA program increased by 20% sequentially from the second quarter to the third quarter of 2025, and has grown 157% since the program's launch. This growth in recurring revenue is crucial. Here's the quick math: recurring revenue streams stabilize the business against the lumpiness of system sales, which is why the company is focused on signing three to five additional multi-site FDA customers in 2025.

Driving Innovation and Future Growth with TDI

A vision for the future demands a robust product pipeline. Sensus Healthcare is pushing innovation with its highly anticipated TransDermal Infusion (TDI) system, which is currently under 510(k) review by the FDA. This next-generation system is designed for deeper, more targeted tissue treatment, expanding their addressable market beyond skin cancer and keloids into new oncology and aesthetic applications.

The company's investment in this future is clear in the numbers: Research and Development (R&D) expense for the first nine months of 2025 was $5.9 million, a significant jump from $2.7 million in the same period of 2024. This increase is largely tied to product development for the next-generation system and lobbying efforts for billing code reimbursement. The expectation is that the FDA determination on TDI, anticipated by the end of 2025, will unlock a new chapter of growth. You can read more about their history and business model here: Sensus Healthcare, Inc. (SRTS): History, Ownership, Mission, How It Works & Makes Money

Core Values: Financial Resilience and Strategic Execution

A core value for any medical device company is financial stability, and Sensus Healthcare has maintained a strong balance sheet to weather the domestic sales slowdown. They exited the third quarter of 2025 with $24.5 million in cash and cash equivalents and no outstanding debt. This cash position is the bedrock for their strategic execution.

Strategic actions that reflect their core value of execution include:

• Maintaining close to 100 SRT systems in inventory to meet anticipated demand.
• Securing finalization of the long-sought-after SRT codes from the Centers for Medicare & Medicaid Services (CMS), validating their technology.
• Expanding the role of President Michael Sardano to include Chief Commercial Officer, signaling a focus on commercial growth.

Sensus Healthcare, Inc. (SRTS) Core Values

You're looking for the bedrock of Sensus Healthcare, Inc. (SRTS)-the principles that actually drive their financial and operational decisions, not just the words on a plaque. For a seasoned analyst, the core values are only as good as the numbers that back them up. The company's focus is clear: to make non-invasive skin cancer treatment the standard of care globally.

This mission is supported by a few key guiding principles that show up directly in their 2025 fiscal year results. Their vision is to be the worldwide leader in delivering non-invasive and pain free treatments for skin cancer, with their Superficial Radiation Therapy (SRT) becoming the primary treatment option. Here's how they're executing on that vision and their core values.

Patient-Centric Care & Accessibility

This value is about ensuring the patient's well-being and making the best treatment accessible, which means removing the financial barriers for the clinics that serve them. Sensus Healthcare's mission is to provide best-in-class non-invasive and minimally-invasive treatments that improve the lives of patients around the world. This isn't just a feel-good statement; it's a business model.

The company's Fair Deal Agreement (FDA) program is the clearest example of this value in action. This model allows healthcare providers to get the SRT system with minimal upfront capital, which in turn expands patient access to non-surgical treatment options. This strategy is paying off: Fair Deal Agreement treatment volume rose 27% sequentially in the second quarter of 2025, and then another 20% in the third quarter of 2025. That's a strong, consistent uptake, showing the model is defintely gaining traction and delivering value to both the company and its customers.

• SRT systems shipped: 56 units in the first nine months of 2025.
• FDA treatment volume: 20% sequential increase in Q3 2025.

Innovation & Clinical Excellence

You can see a company's true commitment to innovation by looking at its Research and Development (R&D) spending. Sensus Healthcare is dedicated to driving advancements in the healthcare field through great technology. They are not just selling existing units; they are investing heavily in the future of their technology and clinical validation.

Here's the quick math: R&D expense for the first nine months of 2025 surged to $5.9 million, a significant jump from $2.7 million in the same period a year earlier. This increase reflects investment in next-generation systems and the TransDermal Infusion (TDI) product, plus significant lobbying costs. That lobbying effort, while costly, was a strategic move to ensure the clinical excellence of SRT is recognized by the system, leading to a huge win for the entire industry.

Customer Focus & Value Creation

Being customer-focused means more than just being responsive; it means actively working to ensure your product provides long-term, sustainable value for the provider. Sensus Healthcare demonstrated this by tackling the reimbursement complexity head-on.

The biggest evidence of this commitment in 2025 was the Centers for Medicare & Medicaid Services (CMS) establishing first-ever dedicated CPT® codes for Superficial Radiation Therapy in the third quarter. This move provides 'reimbursement certainty' and 'compelling economics' for the physicians and clinics using the SRT systems. Plus, they expanded their reach by engaging Radiology Oncology Systems (ROS) as a primary distribution partner, which builds upon their strong base in dermatology and supports broader adoption in hospital settings. This action directly supports their customers by expanding the market and validating the technology's value proposition.

If you want to dive deeper into the financial mechanics of how these values translate to the balance sheet, you should check out Breaking Down Sensus Healthcare, Inc. (SRTS) Financial Health: Key Insights for Investors. They ended the third quarter of 2025 with a strong balance sheet, holding $24.5 million in cash and no debt, which gives them the financial firepower to keep backing these core values.